Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 469-477

  Chon, Young Eun ^a   Kim, Seung Up ^a   Lee, Chun Kyon ^b   Heo, Jeong ^c   Kim, Ja Kyung ^a,d   Yoon, Ki Tae ^c   Cho, Mong ^c   Lee, Kwan Sik ^a,d   Kim, Dong Hwan ^b   Choi, Eun Hee ^a   Park, Jun Yong ^a,d   Kim, Do Young ^a,d   Chon, Chae Yoon ^a,d   Han, Kwang Hyub ^a,d   Ahn, Sang Hoon ^a,d  

^a Yonsei University College of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; YOUDEN INDEX;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959414279     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1772     Document Type: Article

References (37)

1. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 2010; 28:589-590.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745. (Pubitemid 27527771)
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
4. Iloeje UH, Yang HI, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
5. Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
6. Liaw YF, Leung N, Kao J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
8. Ahn SH, Chan HL, Chen P, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4:386-395.
9. European Association For The Study Of The Liver UH. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
10. Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009; 50:644-647.
11. Lai CL, Gane E, Liaw Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
12. Safadi R, Xie Q, Chen Y, Yin Y-K, Weis Y, Hwang S. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at Week 24. J Hepatol 2007; 46 Suppl 1:S196.
13. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
15. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
16. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
17. Leung N, Peng C, Hann H, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72-79.
18. Tenney DJ, Pokornowski KA, Rose RE. Entecavir maintains a high genetic barrier to HBV resistance through 6 years of naive patients. J Hepatol 2009; 50 Suppl 1:S10.
19. Guo JJ, Li Q, Shi X, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res 2009; 81:180-183.
20. Suzuki F, Akuta N, Suzuki Y, et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007; 39:149-152. (Pubitemid 46777428)
21. Cho JH, Yoon K, Lee K, et al. Distribution of hepatitis B virus genotypes in Korea. Korean J Hepatol 2009; 15:140-147.
22. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20:816-820.
23. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005; 48:133-137.
24. Cho JH, Park D, Kim T, et al. Genotypes of hepatitis B virus on Jeju island. Korean J Hepatol 2004; 10:42-50.
25. Lee JM, Kim HJ, Park JY, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009; 14:705-712.
26. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34:1000-1005. (Pubitemid 33032035)
27. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118:760-764. (Pubitemid 30171625)
28. Kim Do Y, Ahn SH, Lee HW, et al. Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. Intervirology 2008; 51:293-298.
29. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265. (Pubitemid 47171942)
30. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42:188-194. (Pubitemid 40143464)
31. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai C. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46:1695-1703.
32. Kim Do Y, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 2009; 54:1758-1763.
33. Kim SU, Han K, Nam CM, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 2008; 23:1722-1727.
34. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35.
35. Perrillo RP, Marcellin P. Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. Antivir Ther 2010; 15:13-22.
36. Yao GB, Ren H, Xu D, et al. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009; 17:881-886.
37. Pan C, Hu K. Excellent treatment response to tenofovir (TDF) monotherapy in chronic hepatitis B (CHB) patients with prior suboptimal response to entecavir (ETV) monotherapy. Hepatology 2008; 48 Suppl 1:725A.